Iovance's AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma -February 16, 2024 at 03:20 pm EST

AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune...

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Iovance Biotherapeutics ,Sara Pellegrino ,Jen Saunders ,Frederick Vogt ,Alexandern Shoushtari ,Steven Rosenberg ,Samanthar Guild ,Nasdaq ,Iovance Biotherapeutics Inc ,Melanoma Foundation ,Surgery Branch ,Treatment Centers Atcs ,Globenewswire Inc ,Drug Administration ,Exchange Commission ,Memorial Sloan Kettering Cancer Center ,National Cancer Institute Surveillance ,Investor Relations Corporate Communications ,Cellular Therapy Service ,National Cancer Institute ,European Medicines Agency ,Iovance Cell Therapy Center ,Authorized Treatment Centers ,Media Snippet ,Interim Chief Executive Officer ,Response Evaluation Criteria ,Solid Tumors ,Important Safety Information ,Prescribing Information ,Cancer Institute ,Melanoma Oncologist ,Cellular Therapist ,Sloan Kettering Cancer ,Cell Therapy Center ,Cancer Institute Surveillance ,End Results ,Independent Review Committee ,Full Prescribing Information ,Patient Information ,Boxed Warning ,Important Safety ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Medicines Agency ,Vice President ,Investor Relations ,Markets ,